Acute and Genotoxic Profile of a Dimeric Impurity of Cefotaxime

International Journal of Toxicology

Volumn 23, Issue 1, 2004, Pages 41-45

  Agarwal, Shiv Kumar ^a   Bhatnagar, Upendra ^a   Rajesh, Navin ^a  

^a Orchid Chemicals and Pharmaceuticals Ltd   (India)

Author keywords

Acute Toxicity; Cefotaxime; Clastogenic; Dimeric Impurity; Mutagenic

Indexed keywords

CEFOTAXIME;

ACUTE TOXICITY; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; CELL CULTURE; CELL DENSITY; CHO CELL; CHROMOSOME ABERRATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOTOXICITY; DRUG IMPURITY; DRUG MANUFACTURE; DRUG STORAGE; FEMALE; GENOTOXICITY; GROWTH INHIBITION; IN VITRO STUDY; METABOLIC ACTIVATION; MUTAGENICITY; NONHUMAN; POINT MUTATION; SALMONELLA TYPHIMURIUM;

ANIMALS; BODY WEIGHT; CEFOTAXIME; CEPHALOSPORINS; CHO CELLS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHROMOSOME BREAKAGE; COMPUTER SIMULATION; CRICETINAE; DRUG CONTAMINATION; INJECTIONS, INTRAMUSCULAR; MAGNETIC RESONANCE SPECTROSCOPY; MASS SPECTROMETRY; MITOTIC INDEX; MUTAGENS; RATS; RATS, SPRAGUE-DAWLEY; SALMONELLA TYPHIMURIUM;

ANIMALIA; BACTERIA (MICROORGANISMS); CRICETINAE; CRICETULUS GRISEUS; MAMMALIA; SALMONELLA TYPHIMURIUM;

EID: 1542619491     PISSN: 10915818     EISSN: None     Source Type: Journal    
DOI: 10.1080/10915810490265441     Document Type: Article

References (13)

1. AHFS drug information. 2002. Bethesda, MD: American Society of Health Systems Pharmacists.
2. ANDAs impurities in drug products. 1998. Guidance for Industry, Food and Drug Administration. U.S. Department of Health and Human Services, Center for Drug Evaluation and Research (CDER), pp 1-14.
3. Aventis Pharmaceuticals. 2002. Prescribing information, 1-4. Bridgewater, NJ: Aventis Pharmaceuticals.
4. Impurities in Drug Substances ... ANDAs. 2000. Int. J. Generic Drugs 3:365-379.
5. International Conference on Harmonisation (ICH). 2000a. Draft revised guidance on impurities in new drug products. Federal Registrar 65:44791-44797.
6. ICH. 2000b. Guidance on Q6A specification: Test procedures and acceptance criteria for new drug substances and new drug products: Chemical substance. Federal Register 65:83041-83061.
7. Maron, D. M., and B. M. Ames. 1983. Revised methods for the Salmonella mutagenicity test. Mutat. Res. 113:173-215.
8. NKRZAZ Chemotherapy (Tokyo). 1980. (Nippon Kagaku Ryoho Gakkai, 2-20-8 Kamiosaki, Shinagawa-Ku, Tokyo 141, Japan.) V.1-1953-28 (Suppl. 1):98.
9. OECD guidelines for testing of chemicals. 1987. Number 401.
10. Penalvo, G. C., G. Castaneda, E. Julien, and H. Fabre. 1996. Cross validation of capillary electrophoresis and high performance liquid chromatography for cefotaxime and related impurities. Chromatographia 42:159-164.
11. Pharmeuropa. 2002. 14.3, 14:422-424.
12. U.S. Environmental Protection Agency. 1998. Health effects test guidelines. OPPTS 870.5375 EPA 712-C-98-223.
13. Venitt, S., C. Crofton-Sleigh, and R. Forster. 1990. Bacterial mutation assays using reverse mutation. In Mutagenicity testing - a practical approach, ed. S. Venitt and J. M. Parry, 49-57. Oxford, England: IRL Press.